UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN INSTITUTIONAL LLC and PFIZER INC.,

Petitioners,

v.

NOVO NORDISK A/S,

Patent Owner.

Case No. IPR2020-00324¹ U.S. Patent No. 8,114,833

DECLARATION OF LARA J. DUEPPEN

¹ IPR2020-01252 has been joined with this proceeding.

DOCKE

Δ

I, Lara J. Dueppen, declare as follows:

1. I am an attorney and partner at Perkins Coie LLP, and counsel for Petitioner Mylan Institutional LLC ("Mylan" or "Petitioner") in connection with the above-captioned *inter partes* review ("IPR").

2. I am over the age of eighteen and otherwise competent to make this Declaration. I have personal knowledge of the facts set forth in this Declaration and am competent to testify to the same.

Exhibit 1131 is a true and correct copy of an email that I received 3. from the Patent Trial and Appeal Board End End to System (PTABE2E_System@uspto.gov) on March 5, 2021 ("Motion Filed Notice"), notifying the parties that Petitioners' Motion to Exclude Evidence (Document No. 54) was filed in IPR2020-00324. The email was also addressed to others, including Jeffrey Oelke T. Moran (joelke@fenwick.com), Laura (laura.moran@fenwick.com), and Ryan P. Johnson (ryan.johnson@fenwick.com), counsel for Patent Owner Novo Nordisk A/S.

Exhibit 1132 is a true and correct copy of an email that I received 4. from Patent Board the Trial and Appeal End to End System (PTABE2E_System@uspto.gov) on March 5, 2021 ("Document Filing Notice"), notifying the parties that Petitioners' Motion to Exclude Evidence (Document No. 54) was filed in IPR2020-00324. The email was also addressed to others, including

Jeffrey Oelke (joelke@fenwick.com), Laura T. Moran (laura.moran@fenwick.com), and Ryan P. Johnson (ryan.johnson@fenwick.com), counsel for Patent Owner Novo Nordisk A/S.

March 19, 2021

Respectfully submitted,

<u>/s/ Lara J. Dueppen</u> Lara J. Dueppen